Fig. 4. CXCL9 and CXCL10 are expressed by different cell types during vitiligo progression. a.

Epidermal cell types represented as a % of total RFP⁺ gate and b. total BFP⁺ gate. c. Percent of each cell type producing CXCL9 or d. CXCL10 over time. (n=19 naïve mice, 5 mice at week 3, 9 at week 5, 12 at week 7, and 9 at week 10 pooled from 2 to 3 separate experiments; two-way ANOVAs significant). e. Vitiligo skin ellipse biopsies demonstrate keratinocytes and LHC expressing CXCL9 and CXCL10 in lesions (10x; representative images from 1 of 7 patients evaluated; Langerin, CXCL9, or CXCL10 antibodies were used to stain sections as indicated to identify Langerhans cells and chemokine-producing cells, respectively, and keratinocytes were identified based on their morphology, epidermal location, and negative Langerin staining; white arrows indicate dual staining of Langerin and chemokines; scale bar = 250μm).